Cargando…
Tissue pharmacokinetics of DHP107, a novel lipid‐based oral formulation of paclitaxel, in mice and patients by positron emission tomography
DHP107 is a newly developed lipid‐based oral formulation of paclitaxel. We evaluated the in vivo tissue pharmacokinetics (PKs) of DHP107 in mice and patients using positron emission tomography (PET). Radioisotope‐labeled [(3)H]DHP107 and [(18)F]DHP107 for oral administration were formulated in the s...
Autores principales: | Moon, Byung Seok, Park, Hyun Soo, Sunwoo, Jung, Lee, In‐Hyun, Kim, Anhye, Moon, Seol Ju, Lee, Heechan, Son, Min Hee, Kim, Su Bin, Park, Sun Mi, Woo, Sang‐Keun, Jang, Jun‐Hee, Kim, Bom Sahn, Kim, Jee Hyun, Kim, Sang Eun, Lee, Howard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504807/ https://www.ncbi.nlm.nih.gov/pubmed/34085761 http://dx.doi.org/10.1111/cts.13003 |
Ejemplares similares
-
DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy
por: Jang, Eunseo, et al.
Publicado: (2019) -
A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
por: Ryu, Min‐Hee, et al.
Publicado: (2017) -
Phase II study of DHP107 (oral paclitaxel) in the first-line
treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL
study)
por: Kim, Sung-Bae, et al.
Publicado: (2021) -
Feasibility of TSPO-Specific Positron Emission Tomography Radiotracer for Evaluating Paracetamol-Induced Liver Injury
por: Kim, Daehee, et al.
Publicado: (2021) -
New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients
por: Kim, Yu Kyong, et al.
Publicado: (2017)